Search

Your search keyword '"de Vos, M."' showing total 133 results
Start Over Author "de Vos, M." Journal human reproduction
133 results on '"de Vos, M."'

8. P-251 Cumulus cell analysis as a non-invasive oocyte selection strategy to reduce the number of oocytes/embryos cultured and increase pregnancy rates

Author

Adriaenssens, T, primary, Van Vaerenbergh, I, additional, Reis, M, additional, Van Landuyt, L, additional, Verheyen, G, additional, Debrucker, M, additional, Camus, M, additional, Platteau, P, additional, De Vos, M, additional, Coucke, W, additional, Vanhecke, E, additional, Rosenthal, A, additional, and Smitz, J, additional

Published
2022
Full Text
View/download PDF

31. Impact of ARTs on oncological outcomes in young breast cancer survivors

Author

Condorelli, M, primary, De Vos, M, additional, Lie Fong, S, additional, Autin, C, additional, Delvigne, A, additional, Vanden Meerschaut, F, additional, Wyns, C, additional, Imbert, R, additional, Cheruy, C, additional, Bouziotis, J, additional, de Azambuja, E, additional, Delbaere, A, additional, Lambertini, M, additional, and Demeestere, I, additional

Published
2020
Full Text
View/download PDF

36. In vitro differentiation of human oocyte-like cells from oogonial stem cells: single-cell isolation and molecular characterization

Author

Blockeel, C., Racca, A., De Munck, N., Santos-Ribeiro, S., Valenzuela, J. Errazuriz, Drakopoulos, P., Galvao, A., De Vos, M., Tournaye, H., Surgical clinical sciences, Reproduction and Genetics, Centre for Reproductive Medicine - Gynaecology, Faculty of Medicine and Pharmacy, Follicle Biology, and Biology of the Testis

Subjects
0301 basic medicine, Ovarian Cortex, Growth Differentiation Factor 9, Cell Cycle Proteins, Synaptonemal complex protein 3, Cell Separation, In Vitro Techniques, Growth differentiation factor-9, ovarian neo-oogenesis, Oogenesis, Germline, Oogonial Stem Cells, DEAD-box RNA Helicases, Andrology, 03 medical and health sciences, Obstetrics and Gynaecology, medicine, Humans, oocytes, In Situ Hybridization, Fluorescence, oogonial stem cells, biology, medicine.diagnostic_test, Rehabilitation, Nuclear Proteins, DEAD box polypeptide 4, Obstetrics and Gynecology, Cell Differentiation, single-cell isolation, DNA-Binding Proteins, 030104 developmental biology, Reproductive Medicine, biology.protein, Female, Antibody, Fluorescence in situ hybridization
Abstract

STUDY QUESTION Are the large cells derived from cultured DEAD box polypeptide 4 (DDX4)-positive oogonial stem cells (OSCs), isolated from the ovarian cortex of non-menopausal and menopausal women, oocyte-like cells? SUMMARY ANSWER Under appropriate culture conditions, DDX4-positive OSCs from non-menopausal and menopausal women differentiate into large haploid oocyte-like cells expressing the major oocyte markers growth differentiation factor 9 (GDF-9) and synaptonemal complex protein 3 (SYCP3) and then enter meiosis. WHAT IS KNOWN ALREADY The recent reports of OSCs in the ovaries of non-menopausal and menopausal women suggest that neo-oogenesis is inducible during ovarian senescence. However, several questions remain regarding the isolation of these cells, their spontaneous maturation in vitro, and the final differentiation state of the resulting putative oocytes. STUDY DESIGN, SIZE, DURATION DDX4-positive OSCs were obtained from 19 menopausal and 13 non-menopausal women (who underwent hysterectomy for uterine fibroma, ovarian cyst, or other benign pathologies) and cultured for up to 3 weeks. Large and small cells were individually isolated and typed for early and late differentiation markers. PARTICIPANTS/MATERIALS, SETTING, METHODS Ovarian cortex fragments were processed by immuno-magnetic separation using a rabbit anti-human DDX4 antibody and the positive populations were measured by assessing both FRAGILIS and stage-specific embryonic antigen 4 (SSEA-4) expression. After 3 weeks in culture, large oocyte-like cells were individually isolated by DEPArray based on PKH26 red staining and cell size determination. GDF-9 and SYCP3 as final, and developmental pluripotency-associated protein 3 (DPPA3) as primordial, germline markers were measured by droplet digital PCR. The haploid versus diploid chromosomal content of chromosomes X and 5 was investigated using fluorescence in situ hybridization (FISH). MAIN RESULTS AND THE ROLE OF CHANCE SSEA-4 + and FRAGILIS + subsets of DDX4-positive populations were present at lower mean levels in menopausal (SSEA-4 +: 46.7%; FRAGILIS +: 47.5%) than in non-menopausal (SSEA-4 +: 64.9%; FRAGILIS +: 64.8) women (P < 0.05). A comparison of the women's age with the ratio of DDX4-positive cells/cm 3 of ovarian cortex revealed an inverse correlation with OSC number (P < 0.05). Once cultured, cells from both groups differentiated to form large (up to 80 μm) mature oocyte-like cells with typical oocyte morphology. Despite the higher numbers of these cells in cultures from non-menopausal women (37.4 versus 23.7/well; P < 0.001), the intra-culture percentages of large oocyte-like cells did not differ significantly between the two groups. Single large oocyte-like cells isolated from non-menopausal and menopausal women expressed equivalent levels of GDF-9 (e.g. 2.0 and 2.6 copies/μl RNA, respectively) and SYCP3 (e.g. 1.2 and 1.5 copies/μl RNA, respectively) mRNA. The remaining small cells isolated from the cultures expressed large amounts of DPPA3 mRNA (e.g. 5.0 and 5.1 copies/μl RNA, from menopausal and non-menopausal women, respectively), which was undetectable in the large oocyte-like cells. FISH analysis of the large and small cells using probes for chromosomes X and 5 revealed a single signal in the large cells, indicative of chromosome haploidy, whereas in the small cells two distinct signals for each chromosome indicated diploidy. LARGE SCALE DATA Not applicable. LIMITATIONS, REASONS FOR CAUTION Our study demonstrated the final differentiation of OSCs, collected from the ovarian cortex of adult women, to oocyte-like cells. However, because the rate of differentiation was low, a major role of the stem cell niche housing these OSCs cannot be ruled out. WIDER IMPLICATIONS OF THE FINDINGS Since the ability of OSCs to generate mature oocytes in vitro is highly variable, the viability of these cells in the ovarian cortex of non-menopausal and menopausal women may well be determined by the stem cell niche and the woman's concurrent reproductive state. Our study showed that the oocyte-like cells obtained by OSC differentiation in vitro, including those from the OSCs of menopausal women, express markers of meiosis. This model of ovarian neo-oogenesis will contribute to the development of approaches to treat female infertility. STUDY FUNDING/COMPETING INTEREST(S) The study was funded by Italian Association for Cancer Research (IG grant 17536), and from the Apulia Region ('Oncogenomic Project' and 'Jonico-Salentino Project'). All Authors declare no competing interests.

Published
2018
Full Text
View/download PDF

39. Do we need to measure progesterone in oocyte donation cycles? A retrospective analysis evaluating cumulative live birth rates and embryo quality

Author

Racca, A, primary, De Munck, N, additional, Santos-Ribeiro, S, additional, Drakopoulos, P, additional, Errazuriz, J, additional, Galvao, A, additional, Popovic, B, additional, Mackens, S, additional, De Vos, M, additional, Verheyen, G, additional, Tournaye, H, additional, and Blockeel, C, additional

Published
2020
Full Text
View/download PDF

41. DNA methylation and mRNA expression of imprinted genes in blastocysts derived from an improved in vitro maturation method for oocytes from small antral follicles in polycystic ovary syndrome patients

Author

Saenz-de-Juano, M D, primary, Ivanova, E, additional, Romero, S, additional, Lolicato, F, additional, Sánchez, F, additional, Van Ranst, H, additional, Krueger, F, additional, Segonds-Pichon, A, additional, De Vos, M, additional, Andrews, S, additional, Smitz, J, additional, Kelsey, G, additional, and Anckaert, E, additional

Published
2019
Full Text
View/download PDF

43. Parameters of poor prognosis in preimplantation genetic testing for monogenic disorders.

Author

Kelen, A Van Der, Santos-Ribeiro, S, Vos, A De, Verdyck, P, Rycke, M De, Berckmoes, V, Tournaye, H, Blockeel, C, Vos, M De, Hes, F J, Keymolen, K, Verpoest, W, Van Der Kelen, A, De Vos, A, De Rycke, M, and De Vos, M

Subjects
GENETIC testing, PROGNOSIS, MICROSATELLITE repeats, MULTIPLE regression analysis, INDUCED ovulation, INFERTILITY, OVARIAN cancer, RETROSPECTIVE studies, PREGNANCY outcomes, FERTILIZATION in vitro, LONGITUDINAL method
Abstract

Study Question: What is the likelihood of success of a single cycle of preimplantation genetic testing for monogenic disorders (PGT-M), measured as the cumulative live birth rate (CLBR) and based on various patient demographics?Summary Answer: For all women aged ≤40 years, the CLBR was at least 10% when the number of oocytes was ≥7 (range 10-30%) or was at least 5% when the number of oocytes was ≥3 (range 5-17%).What Is Known Already: The number of oocytes is significantly associated with the number of embryos for genetic testing and the clinical outcome in PGT-M. Embryos diagnosed as affected or embryos that remain without diagnosis cannot be used for embryo transfer. The size of the group of embryos non-suitable for transfer varies between 25% and 81%, depending on the indication. Thus, PGT-M is more likely to be more severely impacted by suboptimal ovarian response, poor fertilization and suboptimal embryo development than conventional IVF/ICSI schemes without PGT.Study Design, Size, Duration: This was a single-centre retrospective comparative cohort study, of cycles between January 2011 and December 2015. A total number of 2265 PGT-M cycles were compared to 2833 conventional ICSI cycles. The principal aim of our study was the identification of the parameters of poor CLBR in couples undergoing PGT-M using multiplex short tandem repeat (STR) markers on blastomere biopsy DNA. The secondary aim was to compare the parameters of poor CLBR of the PGT-M population to those of couples undergoing ICSI without PGT.Participants/materials, Setting, Methods: The baseline characteristics of the PGT-M group were compared to the conventional ICSI group. A multiple regression analysis was applied to account for the following potential confounding factors: female age, number of previous ART cycles, number of oocytes/suitable embryos for transfer and dosage of gonadotrophins used for ovarian stimulation.Main Results and the Role Of Chance: The PGT-M group was younger (female age 32.0 vs 34.5 years), had a higher number of previous ART cycles (1.1 vs 0.9 cycles) and used more gonadotrophins (2367 vs 1984 IU). Per cycle, the PGT-M group had more retrieved oocytes (11.8 vs 8.3 oocytes), fewer suitable embryos for transfer (1.7 vs 2.8 embryos) and a lower CLBR (29.4% vs 35.0%). Multiple regression analysis showed that the CLBR in the PGT-M group was significantly influenced by female age, the number of previous ART cycles, the number of oocytes and the dose of ovarian stimulation. In both groups, the predicted CLBR increased with increasing numbers of oocytes and suitable embryos. At least two retrieved oocytes or one embryo per single PGT-M cycle could confer an estimated CLBR above 10%. By assessing female age and the number of retrieved oocytes together, it was shown that for all women aged ≤40 years, the predicted CLBR per single PGT-M cycle was ≥10% when the number of oocytes was ≥7 or was ≥5% when the number of oocytes was ≥3.Limitations, Reasons For Caution: Despite the large sample size, the findings are confined by limited confounder adjustment and the lack of specific PGT-M comparators.Wider Implications Of the Findings: This study aimed to describe the likelihood of success of PGT-M treatment, measured as CLBR, based on various patient demographics. In a PGT-M program, couples need to be informed of the prognosis more specifically when it is futile. The table of predicted CLBRs presented in this study is a useful tool in counselling PGT-M couples for making reproductive choices.Study Funding/competing Interest(s): No funding was required and there are no competing interests.Trial Registration Number: N/A. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Impact of ARTs on oncological outcomes in young breast cancer survivors.

Author

Condorelli, M, Vos, M De, Fong, S Lie, Autin, C, Delvigne, A, Meerschaut, F Vanden, Wyns, C, Imbert, R, Cheruy, C, Bouziotis, J, Azambuja, E de, Delbaere, A, Lambertini, M, Demeestere, I, De Vos, M, Lie Fong, S, Vanden Meerschaut, F, and de Azambuja, E

Subjects
BREAST cancer, CANCER survivors, PROGNOSIS, FERTILITY preservation, CANCER relapse, ANTI-Mullerian hormone, INFERTILITY, CANCER hormone therapy, HOT flashes, RESEARCH, RESEARCH methodology, RETROSPECTIVE studies, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, BREAST tumors, LONGITUDINAL method
Abstract

Study Question: What is the risk of recurrence in young breast cancer survivors who undergo ARTs following completion of anticancer treatment?Summary Answer: ART in breast cancer survivors does not appear to have a negative impact on disease-free survival.What Is Known Already: In healthy women, fertility treatment does not increase the risk of developing breast cancer. At the time of breast cancer diagnosis and before starting anticancer treatments, several studies have shown the safety of performing ART. However, the safety of ART in breast cancer survivors following completion of anticancer treatment remains under-investigated. In general, breast cancer survivors are counselled to avoid any hormonal treatment but there are limited data available on the effect of short exposure to high oestradiol levels during ART. The largest study in this regard included 25 breast cancer survivors exposed to ART and did not show a detrimental effect of ART on patient survival. Hence, taking into account that pregnancy after breast cancer does not affect cancer prognosis, defining the safety of ART in breast cancer survivors remains a priority.Study Design, Size, Duration: We conducted a retrospective multicentric matched cohort study including a cohort of breast cancer survivors who underwent ART (exposed patients) between January 2006 and December 2016. Exposed patients who were eligible for the study were matched according to known breast cancer prognostic factors. Matched breast cancer survivors did not undergo ART (non-exposed patients) and were disease-free for a minimum time that was not less than the time elapsed between breast cancer diagnosis and first ART for the matched ART-exposed patients.Participants/materials, Setting, Methods: Data were retrieved from all survivors who had been diagnosed with breast cancer in eight participating centres at an age of ≤40 years, without metastasis, ongoing pregnancy, pre-existing neoplasia or ovarian failure. ART included ovarian stimulation for IVF/ICSI, clomiphene citrate treatment and hormone replacement therapy for embryo transfer. Data were collected from an oncological database for the selection of breast cancer patients in the non-exposed group. Exposed patients were matched (1:2) for germline BRCA status, tumour stage, anticancer treatment and age, whenever feasible. Matched groups were compared at baseline according to characteristics using conditional logistic regression. Kaplan-Meier curves were constructed to compare time to recurrence between groups, with the time of ART as starting point that has been adjusted in the non-exposed group. The analyses were performed using Stata IC/15.1.Main Results and the Role Of Chance: A total of 39 breast cancer patients in the ART group were eligible for the analysis and were matched with 73 controls. There was no statistical difference between the two groups for the presence of BRCA mutation, tumour characteristics, use of (neo)adjuvant chemotherapy and of adjuvant endocrine therapy. Exposed patients were younger than non-exposed patients (mean age 31.8 vs 34.3 years, respectively; P < 0.001). In the ART group, 89.7% were nulliparous at diagnosis compared to 46.6% of controls (P < 0.001). ART was performed at a mean age of 37.1 years old, after a median time of 4.1 years following breast cancer diagnosis (range: 1.5-12.5). Median anti-Müllerian hormone at the time of ART was 0.28 ng/ml (range: 0-4.4) and median serum oestradiol peak level was 696.5 pg/ml (range: 139.7-4130). Median follow-up time from first attempt of ART was 4.6 years (range: 2.4-12.5) in the ART group. Adjusted follow-up time for the non-exposed group was 6.9 years (range: 1.1-16.5 years) (P = 0.004). In the ART group, 59% of patients had a pregnancy after breast cancer compared to 26% in the non-exposed patients (P = 0.001). Breast cancer relapsed in 7.7% versus 20.5% women in the ART and non-exposed groups, respectively (hazard ratio 0.46, 95% CI 0.13-1.62, P = 0.23). Median time to relapse was 1.3 (range: 0.3-2.7) years versus 4.5 (range: 0.4-11.1) years after ART and adjusted time in the ART and non-exposed groups, respectively (P = 0.14).Limitations, Reasons For Caution: Although this is the first and largest multicentric study addressing the impact of ART on breast cancer recurrence to provide data on oestrogen exposure, only a small number of patients could be included. This reflects the reluctance of breast cancer survivors and/or oncologists to perform ART, and highlights the need for a prospective data registry to confirm the safety of this approach. This would offer the possibility for these patients, who are at a high risk of infertility, to fully benefit from ART.Wider Implications Of the Findings: Although recent studies have proven that pregnancy after breast cancer has no detrimental impact on prognosis, counselling patients about the safety of ART remains challenging. Our study provides reassuring data on the use of ART in breast cancer survivors with favourable prognostic factors, for when natural conception fails.Study Funding/competing Interest(s): M.C. and I.D. are funded by FNRS, Télévie-FNRS and Fonds Erasme. M.D.V. is a CooperSurgical scientific advisory board member and receives lecture fees for MSD, Gedeon-Richter and Ferring, outside the submitted work. M.L. has acted as a consultant for Roche and Novartis and has received honoraria from Theramex, Roche, Lilly, Pfizer, Novartis and Takeda, outside the submitted work. I.D. has acted as a consultant for ROCHE and has received speaker's fees from Novartis, outside the submitted work. E.d.A. has received honoraria and is a Roche/GNE, Novartis, SeaGen and Zodiac scientific advisory board member, has received travel grants from Roche/GNE and GSK/Novartis, and has received research grants from Roche/GNE, Astra-Zeneca, GSK/Novartis and Servier, outside the submitted work. A.D. is a recipient of a research grant from Ferring Pharmaceuticals and receives lecture and/or consultancy fees from Merck, Gedeon-Richter and Ferring Pharmaceuticals, outside the submitted work. The remaining authors have no conflicts of interest to declare.Trial Registration Number: N/A. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Male and female fertility preservation

Author

Berthelot-ricou, A., primary, Perrin, J., additional, Roustan, A., additional, Di Giorgio, C., additional, De Meo, M., additional, Botta, A., additional, Orsiere, T., additional, Courbiere, B., additional, Martinez, J. G., additional, Botella, I. M., additional, Casas, I. P., additional, Novella-Maestre, E., additional, Colom, P. J. F., additional, Rubio, J., additional, Martinez, A. P., additional, Rodriguez-Wallberg, K. A., additional, de Mena, S. A., additional, Malm, E., additional, Larsson, A., additional, Kuiper, R., additional, Hassan, M., additional, Herraiz, S., additional, Rodriguez-Iglesias, B., additional, Diaz-Garcia, C., additional, Mirabet, V., additional, Pellicer, A., additional, Aljaser, F. S., additional, Medrano, J. H., additional, Rhodes, S., additional, Tomlinson, M. J., additional, Campbell, B. K., additional, Dong, F., additional, Shi, S., additional, Dai, S., additional, Liu, X., additional, Su, Y., additional, Guo, Y., additional, Wang, F., additional, Xin, Z., additional, Song, W., additional, Jin, H., additional, Sun, Y., additional, Ortega-Hrepich, C., additional, Stoop, D., additional, Guzman, L., additional, Van Landuyt, L., additional, Tournaye, H., additional, Smitz, J., additional, De Vos, M., additional, Diaz, C., additional, Vera, F., additional, Youm, H., additional, Lee, J., additional, Lee, J. r., additional, Lee, J. y., additional, Jee, B. c., additional, Suh, C. s., additional, Kim, S. h., additional, Lotz, L., additional, Hoffmann, I., additional, Muller, A., additional, Hackl, J., additional, Schulz, C., additional, Reissmann, C., additional, Cupisti, S., additional, Oppelt, P. G., additional, Heusinger, K., additional, Hildebrandt, T., additional, Beckmann, M. W., additional, Dittrich, R., additional, Klinger, F., additional, Rossi, V., additional, Lispi, M., additional, Longobardi, S., additional, De Felici, M., additional, Fabbri, R., additional, Vicenti, R., additional, Martino, N. A., additional, Parazza, I., additional, Macciocca, M., additional, Magnani, V., additional, Pasquinelli, G., additional, Dell'Aquila, M. E., additional, Venturoli, S., additional, Fisch, B., additional, Orvieto, R., additional, Fisher, N., additional, Ben-Haroush, A., additional, Stein, A., additional, Abir, R., additional, Al-Samerria, S., additional, McFarlane, J., additional, Almahbobi, G., additional, Klocke, S., additional, Tappehorn, C., additional, and Griesinger, G., additional

Published
2013
Full Text
View/download PDF

49. SESSION 20: FEMALE INFERTILITY 2

Author

Garrido Puchalt, N., primary, Garcia-Velasco, J. A., additional, Rivera, R., additional, Remohi, J., additional, Pellicer, A., additional, Simoes, T., additional, Pinto, S., additional, Marques, C., additional, Correia, S., additional, Pinto, G., additional, Figueiredo, S., additional, Santillan, I., additional, Verdu, V., additional, Parra, M., additional, Bajo, J. M., additional, Macedo, J., additional, Coca, S., additional, Freour, T., additional, Dessolle, L., additional, Lammers, J., additional, Lattes, S., additional, Mansour, W., additional, Mirallie, S., additional, Jean, M., additional, Barriere, P., additional, Polyzos, N. P., additional, Blockeel, C., additional, Verpoest, W., additional, De Vos, M., additional, Stoop, D., additional, Vloeberghs, V., additional, Camus, M., additional, Devroey, P., additional, and Tournaye, H., additional

Published
2012
Full Text
View/download PDF

50. POSTER VIEWING SESSION - EMBRYOLOGY

Author

Fourati Ben Mustapha, S., primary, Khrouf, M., additional, Kacem Ben Rejeb, K., additional, Elloumi Chaabene, H., additional, Merdassi, G., additional, Wahbi, D., additional, Ben Meftah, M., additional, Zhioua, F., additional, Zhioua, A., additional, Azzarello, A., additional, Host, T., additional, Mikkelsen, A. L., additional, Theofanakis, C. P., additional, Dinopoulou, V., additional, Mavrogianni, D., additional, Partsinevelos, G. A., additional, Drakakis, P., additional, Stefanidis, K., additional, Bletsa, A., additional, Loutradis, D., additional, Rienzi, L., additional, Cobo, A., additional, Paffoni, A., additional, Scarduelli, C., additional, Capalbo, A., additional, Garrido, N., additional, Remohi, J., additional, Ragni, G., additional, Ubaldi, F. M., additional, Herrer, R., additional, Quera, M., additional, GIL, E., additional, Serna, J., additional, Grondahl, M. L., additional, Bogstad, J., additional, Agerholm, I. E., additional, Lemmen, J. G., additional, Bentin-Ley, U., additional, Lundstrom, P., additional, Kesmodel, U. S., additional, Raaschou-Jensen, M., additional, Ladelund, S., additional, Guzman, L., additional, Ortega, C., additional, Albuz, F. K., additional, Gilchrist, R. B., additional, Devroey, P., additional, Smitz, J., additional, De Vos, M., additional, Bielanska, M., additional, Leveille, M. C., additional, Borghi, E., additional, Magli, M. C., additional, Figueroa, M. J., additional, Mascaretti, G., additional, Ferraretti, A. P., additional, Gianaroli, L., additional, Szlit, E., additional, Leocata Nieto, F., additional, Maggiotto, G., additional, Arenas, G., additional, Tarducci Bonfiglio, N., additional, Ahumada, A., additional, Asch, R., additional, Sciorio, R., additional, Dayoub, N., additional, Thong, J., additional, Pickering, S., additional, Ten, J., additional, Carracedo, M. A., additional, Guerrero, J., additional, Rodriguez-Arnedo, A., additional, Llacer, J., additional, Bernabeu, R., additional, Tatone, C., additional, Heizenrieder, T., additional, Di Emidio, G., additional, Treffon, P., additional, Seidel, T., additional, Eichenlaub-Ritter, U., additional, Cortezzi, S. S., additional, Cabral, E. C., additional, Ferreira, C. R., additional, Trevisan, M. G., additional, Figueira, R. C. S., additional, Braga, D. P. A. F., additional, Eberlin, M. N., additional, Iaconelli Jr., A., additional, Borges Jr., E., additional, Zabala, A., additional, Pessino, T., additional, Blanco, L., additional, Rey Valzacchi, G., additional, Leocata, F., additional, Vanden Meerschaut, F., additional, Heindryckx, B., additional, Qian, C., additional, Deforce, D., additional, Leybaert, L., additional, De Sutter, P., additional, De las Heras, M., additional, De Pablo, J. L., additional, Navarro, B., additional, Agirregoikoa, J. A., additional, Barrenetxea, G., additional, Cruz, M., additional, Perez-Cano, I., additional, Gadea, B., additional, Herrero, J., additional, Martinez, M., additional, Roldan, M., additional, Munoz, M., additional, Pellicer, A., additional, Meseguer, M., additional, Galindo, N., additional, Scarselli, F., additional, Alviggi, E., additional, Colasante, A., additional, Minasi, M. G., additional, Rubino, P., additional, Lobascio, M., additional, Ferrero, S., additional, Litwicka, K., additional, Varricchio, M. T., additional, Giannini, P., additional, Piscitelli, P., additional, Franco, G., additional, Zavaglia, D., additional, Nagy, Z. P., additional, Greco, E., additional, Urner, F., additional, Wirthner, D., additional, Murisier, F., additional, Mock, P., additional, Germond, M., additional, Amorocho Llanos, B., additional, Calderon, G., additional, Lopez, D., additional, Fernandez, L., additional, Nicolas, M., additional, Landeras, J., additional, Finn-Sell, S. L., additional, Leandri, R., additional, Fleming, T. P., additional, Macklon, N. S., additional, Cheong, Y. C., additional, Eckert, J. J., additional, Lee, J. H., additional, Jung, Y. J., additional, Hwang, H. K., additional, Kang, A., additional, An, S. J., additional, Jung, J. Y., additional, Kwon, H. C., additional, Lee, S. J., additional, Palini, S., additional, Zolla, L., additional, De Stefani, S., additional, Scala, V., additional, D'Alessandro, A., additional, Polli, V., additional, Rocchi, P., additional, Tiezzi, A., additional, Pelosi, E., additional, Dusi, L., additional, Bulletti, C., additional, Fadini, R., additional, Lain, M., additional, Mignini Renzini, M., additional, Brambillasca, F., additional, Coticchio, G., additional, Merola, M., additional, Guglielmo, M. C., additional, Dal Canto, M., additional, Figueira, R., additional, Setti, A. S., additional, Worrilow, K. C., additional, Uzochukwu, C. D., additional, Eid, S., additional, Le Gac, S., additional, Esteves, T. C., additional, van Rossem, F., additional, van den Berg, A., additional, Boiani, M., additional, Kasapi, E., additional, Panagiotidis, Y., additional, Goudakou, M., additional, Papatheodorou, A., additional, Pasadaki, T., additional, Prapas, N., additional, Prapas, Y., additional, Vanderzwalmen, P., additional, Norasing, S., additional, Atchajaroensatit, P., additional, Tawiwong, W., additional, Thepmanee, O., additional, Saenlao, S., additional, Aojanepong, J., additional, Hunsajarupan, P., additional, Sajjachareonpong, K., additional, Punyatanasakchai, P., additional, Maneepalviratn, S., additional, Jetsawangsri, U., additional, Tejera, A., additional, Rubio, I., additional, Romero, J. L., additional, Nordhoff, V., additional, Schlatt, S., additional, Schuring, A. N., additional, Kiesel, L., additional, Kliesch, S., additional, Azambuja, R., additional, Okada, L., additional, Lazzari, V., additional, Dorfman, L., additional, Michelon, J., additional, Badalotti, M., additional, Badalotti, F., additional, Petracco, A., additional, Schwarzer, C., additional, Versieren, K., additional, De Croo, I., additional, Lierman, S., additional, De Vos, W., additional, Van den Abbeel, E., additional, Gerris, J., additional, Milacic, I., additional, Borogovac, D., additional, Veljkovic, M., additional, Arsic, B., additional, Jovic Bojovic, D., additional, Lekic, D., additional, Pavlovic, D., additional, Garalejic, E., additional, Albertini, D. F., additional, De Ponti, E., additional, Sanges, F., additional, Talevi, R., additional, Papini, L., additional, Mollo, V., additional, Rienzi, L. F., additional, Gualtieri, R., additional, Orteg, C., additional, Choi, J., additional, Lee, H., additional, Ku, S., additional, Kim, S., additional, Choi, Y., additional, Kim, J., additional, Moon, S., additional, Demilly, E., additional, Assou, S., additional, Moussaddykine, S., additional, Dechaud, H., additional, Hamamah, S., additional, Takisawa, T., additional, Doshida, M., additional, Hattori, H., additional, Nakamura, Y., additional, Kyoya, T., additional, Shibuya, Y., additional, Nakajo, Y., additional, Tasaka, A., additional, Toya, M., additional, Kyono, K., additional, Novo, S., additional, Penon, O., additional, Gomez, R., additional, Barrios, L., additional, Duch, M., additional, Santalo, J., additional, Esteve, J., additional, Nogues, C., additional, Plaza, J. A., additional, Perez-Garcia, L., additional, Ibanez, E., additional, Chavez, S., additional, Loewke, K., additional, Behr, B., additional, Reijo Pera, R., additional, Huang, S., additional, Wang, H., additional, Soong, Y., additional, Chang, C., additional, Okimura, T., additional, Kuwayama, M., additional, Mori, C., additional, Morita, M., additional, Uchiyama, K., additional, Aono, F., additional, Kato, K., additional, Takehara, Y., additional, Kato, O., additional, Minasi, M., additional, Casciani, V., additional, Arizzi, L., additional, Mencacci, C., additional, Piscitelli, C., additional, Cucinelli, F., additional, Tocci, A., additional, Wydooghe, E., additional, Vandaele, L., additional, Dewulf, J., additional, Van Soom, A., additional, Moon, J. H., additional, Son, W. Y., additional, Mahfoudh, A., additional, Henderson, S., additional, Jin, S. G., additional, Shalom-Paz, E., additional, Dahan, M., additional, Holzer, H., additional, Mahmoud, K., additional, Triki-Hmam, C., additional, Terras, K., additional, Hfaiedh, T., additional, Ben Aribia, M. H., additional, Otsubo, H., additional, Egashira, A., additional, Tanaka, K., additional, Matsuguma, T., additional, Murakami, M., additional, Murakami, K., additional, Otsuka, M., additional, Yoshioka, N., additional, Araki, Y., additional, Kuramoto, T., additional, Smit, J. G., additional, Sterrenburg, M. D., additional, Eijkemans, M. J. C., additional, Al-Inany, H. G., additional, Youssef, M. A. F. M., additional, Broekmans, F. J. M., additional, Willoughby, K., additional, DiPaolo, L., additional, Deys, L., additional, Lagunov, A., additional, Amin, S., additional, Faghih, M., additional, Hughes, E., additional, Karnis, M., additional, Ashkar, F., additional, King, W. A., additional, Neal, M. S., additional, Antonova, I., additional, Veleva, L., additional, Petkova, L., additional, Shterev, A., additional, Nogales, C., additional, Martinez, E., additional, Ariza, M., additional, Cernuda, D., additional, Gaytan, M., additional, Linan, A., additional, Guillen, A., additional, Bronet, F., additional, Cottin, V., additional, Fabian, D., additional, Allemann, F., additional, Koller, A., additional, Spira, J. C., additional, Agudo, D., additional, Martinez-Burgos, M., additional, Arnanz, A., additional, Basile, N., additional, Rodriguez, A., additional, Cho, Y. S., additional, Filioli Uranio, M., additional, Ambruosi, B., additional, Paternoster, M. S., additional, Totaro, P., additional, Sardanelli, A. M., additional, Dell'Aquila, M. E., additional, Zollner, U., additional, Hofmann, T., additional, Zollner, K. P., additional, Kovacic, B., additional, Roglic, P., additional, Vlaisavljevic, V., additional, Sole, M., additional, Boada, M., additional, Coroleu, B., additional, Veiga, A., additional, Martiny, G., additional, Molinari, M., additional, Revelli, A., additional, Chimote, N. M., additional, Chimote, M., additional, Mehta, B., additional, Chimote, N. N., additional, Sheikh, N., additional, Nath, N., additional, Mukherjee, A., additional, Rakic, K., additional, Reljic, M., additional, Ingerslev, H. J., additional, Kirkegaard, K., additional, Hindkjaer, J., additional, Agerholm, I., additional, Kitasaka, H., additional, Fukunaga, N., additional, Nagai, R., additional, Yoshimura, T., additional, Tamura, F., additional, Kitamura, K., additional, Hasegawa, N., additional, Nakayama, K., additional, Katou, M., additional, Itoi, F., additional, Asano, E., additional, Deguchi, N., additional, Ooyama, K., additional, Hashiba, Y., additional, Asada, Y., additional, Michaeli, M., additional, Rotfarb, N., additional, Karchovsky, E., additional, Ruzov, O., additional, Atamny, R., additional, Slush, K., additional, Fainaru, O., additional, Ellenbogen, A., additional, Chekuri, S., additional, Chaisrisawatsuk, T., additional, Chen, P., additional, Pangestu, M., additional, Jansen, S., additional, Catt, S., additional, Molinari, E., additional, Racca, C., additional, Ryu, C., additional, Kang, S., additional, Lee, J., additional, Chung, D., additional, Roh, S., additional, Chi, H., additional, Yokota, Y., additional, Yokota, M., additional, Yokota, H., additional, Sato, S., additional, Nakagawa, M., additional, Komatsubara, M., additional, Makita, M., additional, Oyama, K., additional, Naruse, K., additional, Kilani, S., additional, Chapman, M. G., additional, Kwik, M., additional, Chapman, M., additional, Guven, S., additional, Odaci, E., additional, Yildirim, O., additional, Kart, C., additional, Unsal, M. A., additional, Yulug, E., additional, Isachenko, E., additional, Maettner, R., additional, Strehler, E., additional, Isachenko, V., additional, Hancke, K., additional, Kreienberg, R., additional, Sterzik, K., additional, Zheng, X. Y., additional, Wang, L. N., additional, Liu, P., additional, Qiao, J., additional, Inoue, F., additional, Dashtizad, M., additional, Wahid, H., additional, Rosnina, Y., additional, Daliri, M., additional, Hajarian, H., additional, Akbarpour, M., additional, Abbas Mazni, O., additional, Knez, K., additional, Tomaevic, T., additional, Vrtacnik Bokal, E., additional, Zorn, B., additional, Virant Klun, I., additional, Koster, M., additional, Liebenthron, J., additional, Nicolov, A., additional, van der Ven, K., additional, van der Ven, H., additional, Montag, M., additional, Fayazi, M., additional, Salehnia, M., additional, Beigi Boroujeni, M., additional, Khansarinejad, B., additional, Deignan, K., additional, Emerson, G., additional, Mocanu, E., additional, Wang, J. J., additional, Andonov, M., additional, Linara, E., additional, Ahuja, K. K., additional, Nachef, S., additional, Pasqualotto, F. F., additional, Pasqualotto, E., additional, Chang, C. C., additional, Bernal, D. P., additional, Elliott, T. A., additional, Shapiro, D. B., additional, Toledo, A. A., additional, Economou, K., additional, Davies, S., additional, Argyrou, M., additional, Doriza, S., additional, Sisi, P., additional, Moschopoulou, M., additional, Karagianni, A., additional, Mendorou, C., additional, Polidoropoulos, N., additional, Papanicopoulos, C., additional, Stefanis, P., additional, Karamalegos, C., additional, Cazlaris, H., additional, Koutsilieris, M., additional, Mastrominas, M., additional, Gotts, S., additional, Doshi, A., additional, Harper, J., additional, Serhal, P., additional, Borini, A., additional, Guzeloglu-Kayisli, O., additional, Bianchi, V., additional, Seli, E., additional, Lappi, M., additional, Bonu, M. A., additional, Mizuta, S., additional, Hashimoto, H., additional, Kuroda, Y., additional, Matsumoto, Y., additional, Mizusawa, Y., additional, Ogata, S., additional, Yamada, S., additional, Kokeguchi, S., additional, Noda, Y., additional, Shiotani, M., additional, Stojkovic, M., additional, Ilic, M., additional, Markovic, N., additional, Stojkovic, P., additional, Feng, G., additional, Zhang, B., additional, Zhou, H., additional, Zhou, L., additional, Gan, X., additional, Qin, X., additional, Shu, J., additional, Wu, F., additional, Molina Botella, I., additional, Lazaro Ibanez, E., additional, Debon Aucejo, A., additional, Pertusa, J., additional, Fernandez Colom, P. J., additional, Li, C., additional, Zhang, Y., additional, Cui, Y., additional, Zhao, H., additional, Liu, J., additional, Oliveira, J. B. A., additional, Petersen, C. G., additional, Mauri, A. L., additional, Massaro, F. C., additional, Silva, L. F. I., additional, Ricci, J., additional, Cavagna, M., additional, Pontes, A., additional, Vagnini, L. D., additional, Baruffi, R. L. R., additional, Franco Jr., J. G., additional, Felipe, V., additional, Vilela, M., additional, Tiveron, M., additional, Lombardi, C., additional, Viglierchio, M. I., additional, Marconi, G., additional, Rawe, V., additional, Wale, P. L., additional, Gardner, D. K., additional, Nakagawa, K., additional, Sugiyama, R., additional, Nishi, Y., additional, Kuribayashi, Y., additional, Jyuen, H., additional, Yamashiro, E., additional, Shirai, A., additional, Inoue, M., additional, Hovatta, O., additional, Tohonen, V., additional, Inzunza, J., additional, Parmegiani, L., additional, Cognigni, G. E., additional, Bernardi, S., additional, Ciampaglia, W., additional, Infante, F. E., additional, Tabarelli de Fatis, C., additional, Pocognoli, P., additional, Arnone, A., additional, Maccarini, A. M., additional, Troilo, E., additional, Filicori, M., additional, Radwan, P., additional, Polac, I., additional, Borowiecka, M., additional, Bijak, M., additional, and Radwan, M., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results